Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow EOLS
Evolus, Inc. (EOLS) Altman Z-score
Evolus, Inc.'s Altman Z-score for fiscal 2025 is −1.87, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −1.87 | (1.12) |
| FY2024 | −0.75 | 1.06 |
| FY2023 | −1.81 | 0.53 |
| FY2022 | −2.34 | (1.53) |
| FY2021 | −0.81 | 3.92 |
| FY2020 | −4.72 | (4.19) |
| FY2019 | −0.53 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.30 | — | 0.36 | |
| Retained earnings / total assets | (2.93) | — | −4.10 | |
| EBIT / total assets | (0.14) | — | −0.48 | |
| Market value of equity / total liabilities | 1.72 | — | 1.03 | |
| Sales / total assets | 1.32 | — | 1.32 | |
| Altman Z-score | Distress zone | −1.87 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −8.65 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KMDA Kamada Ltd. compare | 3.3× |
| TKNO Alpha Teknova, Inc. compare | 1.8× |
| EBS Emergent Biosolutions Inc. compare | 1.6× |
| COLL Collegium Pharmaceutical, Inc. compare | 1.6× |
| EVO Evotec AG compare | 0.6× |
| EOLS Evolus, Inc. | −1.9× |
| TLRY Tilray Brands, Inc. compare | −2.0× |
| AQST Aquestive Therapeutics, Inc. compare | −2.2× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | −3.7× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets